MINNEAPOLIS--(BUSINESS WIRE)--Urologix®, Inc. (NASDAQ:ULGX), today reported financial results for the fiscal 2008 second quarter ended December 31, 2007. Revenue for the second quarter was $3.8 million, which is 37 percent lower than $6.0 million reported in the same period of fiscal 2007 and 13 percent less than $4.4 million reported in the first quarter of this fiscal year. Net loss for the second quarter was $10.1 million, or $0.71 per diluted share, which includes a net non-cash impairment charge of $8.6 million, or $0.60 per share, from the $10.2 million write-off of goodwill net of the reversal of the related deferred tax liability of $1.6 million. This loss is compared to net income of $147,000 or $0.01 per diluted share, in the second quarter of fiscal 2007. For the six months ended December 31, 2007, revenue was $8.2 million compared to $11.4 million in the prior year period. The net loss for the six months ended December 31, 2007, including the current quarter impairment charge, was $10.5 million, or $0.73 per diluted share, compared to a net loss of $379,000, or $0.03 per diluted share, for the six months ended December 31, 2006.
